An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Completed · Phase 2

Conditions studied: Prostatic Neoplasms, Prostate Cancer

In brief

The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).

Key facts

Study ID

NCT00485303

Run by

Cougar Biotechnology, Inc.

People needed

58

Starts

2007-06-01

Expected to finish

2011-10-01

Last updated by the study team

2013-07-02

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed adenocarcinoma (malignant epithelial tumor with a glandular organization)of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum), but not with neuroendocrine (specialized neurons that produce hormones, such as neuropeptides or biogenic amines) differentiation or of small cell histology
• Prior chemotherapy (treatment of disease, usually cancer, by chemical agents) for prostate cancer with regimen(s) containing docetaxel
• Documented prostate specific antigen (PSA) progression according to Prostate Specific Antigen Working Group (PSAWG) eligibility criteria with a PSA more than (>) 5 nanogram per milliliter (ng/mL) or objective progression by Response Evaluation Criteria in Solid Tumors (RESIST) criteria
• Ongoing androgen deprivation with serum testosterone less than (<) 50 nanogram per deciliter (ng/dL)
• Eastern Cooperative Oncology Group (ECOG) Performance Status of less than equal to (<=) 2 (Karnofsky Performance Status >= 50 percent)

You may not qualify if…

• Active or uncontrolled autoimmune disease (disorder in which a person's immune system attacks parts of his or her own body) that may require corticosteroid therapy
• Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
• Uncontrolled hypertension (high blood pressure)
• Hemoglobin <=9.0 gram per deciliter (g/dL) without growth factor or transfusion support
• Abnormal liver (large organ that helps in many body functions, including digestion, metabolism, and storage of substances) function

Where it is running

• UCLA — Los Angeles, California, United States
• Study site — Los Angeles, California, United States
• UCSF Comprehensive Cancer Center — San Francisco, California, United States
• Study site — San Francisco, California, United States
• John Hopkins — Baltimore, Maryland, United States
• Study site — Baltimore, Maryland, United States
• Masachussetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Beth Israel Hospital — Boston, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Study site — New York, New York, United States
• Royal Marsden Hospital — Sutton, United Kingdom
• Study site — Sutton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.